✦ LIBER ✦

Lack of response to commercial factor VIII concentrate in hemophilia a

✍ Scribed by George M. Rodgers; Marilyn H. Ford

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 113 KB
Volume: 37
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830370419

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response to commercial factor VIII conce

Response to commercial factor VIII concentrate

✍ Edward D. Gomperts; Doris Menache; George M. Rodgers; Marilyn H. Ford 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 1 views

Comparison of continuous and intermitten

Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A

✍ W. E. Hathaway; M. J. Christian; S. L. Clarke; U. Hasiba 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

In vitro reactivity of factor VIII inhib

In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates

✍ Giuseppe Tagariello; Daniela Zanotto; Paolo Radossi; Roberto Sartori; Donata Bel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

Incidence of inhibitors in patients with

Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates

✍ Dr. Iise Schwarzinger; Ingrid Pabinger; Christian Korninger; Ferdinand Haschke; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views

Mutations of the factor VIII gene in Tha

Mutations of the factor VIII gene in Thai hemophilia A patients

✍ V. Akkarapatumwong; S. Oranwiroon; P. Pung-amritt; A. Treesucon; P. Thanootaraku 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 2 views

Hemophilia A is a common X-linked bleeding disorder caused by mutations in the coagulation factor VIII gene. The entire coding and essential sequences of the factor VIII gene were generated by a combination of genomic DNA amplification and long reverse transcription-polymerase chain reaction (long R

Bedside measurement of factor VIII:C act

Bedside measurement of factor VIII:C activity in individuals with hemophilia A

✍ Kessler, C.M.; Bernstein, Z.; Ghesani, S.; Shamsipour, Z.; Frances, C.; Zucker, 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 1 views

Factor Vlll replacement therapy for patients with hemophilia A Is conventionally monitored using a plasma-based factor VII1:C assay (a modified activated partial thromboplastln time [ A P m test). The plasma factor Vlll assay requires the preparation of plasma from cltrated whole blood and measureme